On December 20, Glonghui reported that Shandong Lukang Pharmaceutical (600789.SH) announced that the "Lukang" registered trademark and related product trademarks are owned by Hualu Group. In April 2022, the company reached a trademark licensing agreement with Hualu Group regarding the "Lukang" registered trademark and related product trademarks, charging the company 7.6 million yuan annually as a trademark usage fee, with the agreement valid for three years (2022-2024). Given that the above trademark licensing agreement is about to expire, the company and Hualu Group negotiated to renew the trademark licensing agreement. The annual usage fee is 7.6 million yuan, and other terms of the trademark licensing agreement remain unchanged, with the agreement valid for one year (2025). Hualu Group is the controlling Shareholder of the company, and according to the regulations of the Shanghai Stock Exchange Listing Rules, Hualu Group is a related party of the company. This transaction constitutes a related party transaction and does not require submission to the shareholders' meeting for review. It also does not constitute a major asset reorganization as defined by the Regulations on the Management of Major Asset Restructuring of Listed Companies.